Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Positron emission tomography (PET) allows for minimally invasive in vivo localization of amyloid and tau deposition, and visualization of glucose metabolism using amyloid PET, tau PET, and FDG PET. Clinically, these scans are used to determine A, T, and N (amyloid-β plaques, tau tangles, and neurodegeneration) status in Alzheimer’s disease. In light of the recent anti-amyloid therapies, determination of the A, and the associated T and N status is increasingly important. This review explores the potential of a single PET scan to define multiple biomarkers. A literature search using the PubMed database and an additional citation search using Google Scholar identified 76 relevant publications up to 30 July 2025. Original work reporting amyloid, tau or FDG PET to determine two or more ATN-related biomarkers were included. Non-English, animal, and non-dementia related studies were excluded. For each study, quantitative outcomes such as correlations and ROC AUC scores were extracted and compared. Early phase amyloid and tau PET (n = 58) were consistently found to be good indicators of N status with a median (IQR) correlation of 0.82 (0.76–0.86). Limited research (n = 7) was performed for amyloid or tau PET to infer both A and T status, with tau-based studies having slightly higher ROC AUC scores (0.88–0.99) than amyloid-based studies (0.84–0.9). Initial results are promising (median ROC AUC scores of 0.88 (0.81–0.96)) but need to be validated. FDG PET was found to be less accurate for A or T status (n = 12) prediction (median ROC AUC scores of 0.83 (0.80–0.87)). Among the modalities, tau PET seems to be the most promising candidate for a single tracer approach to predict all three biomarkers.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Balot, E., Vandenberghe, S., Van Langenhove, T., De Meulenaere, V., D’Asseler, Y., & Van Weehaeghe, D. (2025). Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review. Brain Sciences. https://doi.org/10.3390/brainsci15121271

Vancouver

Balot E, Vandenberghe S, Van Langenhove T, De Meulenaere V, D’Asseler Y, Van Weehaeghe D. Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review. Brain Sciences. 2025. doi:10.3390/brainsci15121271. PMID: 41440067.

BibTeX

@article{balot2025-41440067,
  author  = {Balot, Emile and Vandenberghe, Stefaan and Van Langenhove, Tim and De Meulenaere, Valerie and D’Asseler, Yves and Van Weehaeghe, Donatienne},
  title   = {{Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review}},
  journal = {Brain Sciences},
  year    = {2025},
  doi     = {10.3390/brainsci15121271},
  pmid    = {41440067},
  url     = {https://doi.org/10.3390/brainsci15121271}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review of 76 published studies found that early-phase amyloid and tau PET scans were consistently good at indicating neurodegeneration, and that limited research suggests a single PET scan might also help infer amyloid and tau status. The authors describe these initial results as promising but say they still need to be validated.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 37 of 100.37 of 100 points earned63 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Brain Sciences)
Journal's citation record 1 / 4 Brain Sciences: journal h-index 115 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 58 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Donatienne Van Weehaeghe: h-index 23 (OpenAlex, whole career)
Institution's track record 1 / 3 Ghent University: institution h-index 1,033 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41440067)
Free to read 2 / 2 Free to read
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Biomarkers

See all studies in Biomarkers →